{"id":"W2178423748","doi":"10.1016/j.bmcl.2008.03.057","title":"Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor","year":2008,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Chemistry; In vivo; Isopropyl; Potency; Tyrosine kinase; Stereochemistry; Chemical synthesis; Pharmacokinetics; Structure–activity relationship; In vitro; Selectivity; Receptor tyrosine kinase; Kinase; Tyrosine-kinase inhibitor; Enzyme inhibitor; Pharmacology; Receptor; Biochemistry; Medicinal chemistry; Cancer; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007427484,0.0008275139,0.000668985,0.0003929304,0.0001946466,0.000446625,0.0005261608,0.0005039584,0.001380926],"category_scores_gemma":[0.0003840244,0.0004046998,0.0004075774,0.0002144092,0.0003933606,0.0005252223,0.0001436051,0.00120815,0.0006044008],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004908204,"about_ca_system_score_gemma":0.0008613967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000866078,"about_ca_topic_score_gemma":0.002160916,"domain_scores_codex":[0.9997695,0.00005633907,0.00001247086,0.00003345941,0.00003789004,0.00009034437],"domain_scores_gemma":[0.9998393,0.00002865183,0.00003550707,0.00001871193,0.00001324648,0.0000645831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004747171,0.005467732,0.0007579352,0.0002613263,0.0001292976,0.0003686983,0.0001468905,0.002245891,0.9566979,0.001567224,0.00166048,0.02594937],"study_design_scores_gemma":[0.01239218,0.09195483,0.008845203,0.0000433239,0.0004776393,0.001544924,0.00007813191,0.006454406,0.8642678,0.000561048,0.01333386,0.00004665727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821739,0.005050414,0.004749466,0.0008371897,0.0001837267,0.0005431791,0.0009791011,0.0002146187,0.00526841],"genre_scores_gemma":[0.9889014,0.002776066,0.002470549,0.0001862015,0.0001098868,0.0002977589,0.001353359,0.00002438243,0.003880443],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001380926,"threshold_uncertainty_score":0.004619658,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03409842707840115,"score_gpt":0.3030423123951475,"score_spread":0.2689438853167463,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}